AGENUS INC (AGEN) research

AGENUS INC
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$7.85
As of

AGENUS INC (AGEN): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-18.

As of . Source: SEC EDGAR filings for AGEN. Method and limitations.

SHARE THIS CARD

Share the AGEN intelligence card

A branded snapshot of AGEN: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion AGEN intelligence card preview
Post to X
LIVE TERMINAL

See AGEN live in the terminal

Track AGEN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live AGEN terminal, free

Active signals for AGEN

FREE, NO ACCOUNT

Every signal on AGEN, as it fires

You are seeing 5 of 12 signals recorded on AGEN since 2026-06-21.

The five above landed across 2 days. The other 7 were recorded on 2 other days. 8 of the 12 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in AGEN (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 00847G804 · 2026Q2$699K0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 00847G804 · 2026Q2$302K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, AGEN

AGEN against its peers

AGEN's operating margin of -17.7% ranks in the 79th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.

MetricAGENPeer medianPercentilen
Revenue FY114M USD30.9M USD8913
Operating margin-17.7%-279.5%7911
Net margin-2.7%-213.4%8112
Return on equityn/a-42.2%n/a15

Peers (18): IFRX, VNDA, FATE, ABEO, QTTB, SABS, ZNTL, UPB, OBIO, SION, IMRX, CYDY, EYPT, FHTX, STRO, IPSC, PYXS, IKT. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AGEN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more AGEN signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AGENand get the insider, 13F, options, and confluence read in one view.

Open the live AGEN terminal, free